JP2023536815A5 - - Google Patents

Info

Publication number
JP2023536815A5
JP2023536815A5 JP2023505850A JP2023505850A JP2023536815A5 JP 2023536815 A5 JP2023536815 A5 JP 2023536815A5 JP 2023505850 A JP2023505850 A JP 2023505850A JP 2023505850 A JP2023505850 A JP 2023505850A JP 2023536815 A5 JP2023536815 A5 JP 2023536815A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
therapeutic peptide
seq
polyvalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023505850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536815A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038999 external-priority patent/WO2022026092A2/en
Publication of JP2023536815A publication Critical patent/JP2023536815A/ja
Publication of JP2023536815A5 publication Critical patent/JP2023536815A5/ja
Withdrawn legal-status Critical Current

Links

JP2023505850A 2020-07-28 2021-06-24 好中球駆動性炎症性病変の治療方法 Withdrawn JP2023536815A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063057741P 2020-07-28 2020-07-28
US63/057,741 2020-07-28
PCT/US2021/038999 WO2022026092A2 (en) 2020-07-28 2021-06-24 Method of treatment of neutrophil-driven inflammatory pathologies

Publications (2)

Publication Number Publication Date
JP2023536815A JP2023536815A (ja) 2023-08-30
JP2023536815A5 true JP2023536815A5 (enExample) 2024-06-28

Family

ID=80038122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505850A Withdrawn JP2023536815A (ja) 2020-07-28 2021-06-24 好中球駆動性炎症性病変の治療方法

Country Status (7)

Country Link
US (1) US20230285505A1 (enExample)
EP (1) EP4181942A4 (enExample)
JP (1) JP2023536815A (enExample)
CN (1) CN116194143A (enExample)
AU (1) AU2021318793A1 (enExample)
CA (1) CA3185526A1 (enExample)
WO (1) WO2022026092A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1768650T3 (pl) * 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
WO2023183059A1 (en) * 2022-03-24 2023-09-28 Susavion Biosciences, Inc. Method of treatment of neutrophil-driven inflammatory pathologies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
US8460697B2 (en) * 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
ES2316312B1 (es) * 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
WO2013096829A2 (en) * 2011-12-22 2013-06-27 Arizona Biomedical Research Commission Activation of cellular assault processes in the treatment of glioblastoma multiforme
US9155796B2 (en) * 2012-12-04 2015-10-13 Susavion Biosciences, Inc. Hydrogels with covalently linked polypeptides
CA2971471C (en) * 2014-12-19 2023-04-18 Susavion Biosciences, Inc. Immunotherapy treatments and compositions
EP3288576A4 (en) * 2015-04-27 2019-01-16 Susavion Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides

Similar Documents

Publication Publication Date Title
JP2024167362A (ja) 大型薬剤の経皮送達
KR20140043348A (ko) 리포솜 제제
US20190055307A1 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
CN115867304A (zh) 用于治疗阿兹海默症的多抗原决定基疫苗
US11248040B2 (en) Binding moieties for biofilm remediation
CN102245629B (zh) 修饰的淀粉状蛋白β肽
EP2145898A1 (en) Anti-amyloid immunogenic compositions, methods and uses
JPH10509428A (ja) 活性依存性神経栄養因子の神経栄養ペプチド
CN117751132A (zh) 用于治疗阿尔兹海默氏病的tau疫苗
CA2187336A1 (en) Pharmaceutical formulations for treating japanese cedar pollen allergy
TWI333857B (en) Intranasal pharmaceutical composition for treating non-viral induced airway inflammation or allergic diseases and uses thereof
CN101980721B (zh) 含有合成肽的抗原药物赋形剂和使用其的粘膜疫苗
CN102205114A (zh) 促红细胞生成素来源肽在制备治疗神经系统自身免疫性疾病的药物中的应用
JP2020536925A5 (enExample)
JP2020530478A5 (enExample)
AU2018284219A1 (en) Hydrochloride salts of C5a receptor agonist peptides
WO2005058936A2 (de) Dna-sequenz und rekombinante herstellung des graspollen-allergens lol p 4
AU2014324761B2 (en) Binding moieties for biofilm remediation
US10722568B2 (en) Transcutaneous Haemophilius influenzae vaccine formulations and methods
KR100756974B1 (ko) 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트
CA3222356A1 (en) Compositions and methods to increase coronavirus immune response
Moyle et al. Synthesis and Immunological Evaluation of M Protein Targeted Tetra-Valent and Tri-Valent Group A Streptococcal Vaccine Candidates Based on the Lipid-Core Peptide System: Moyle et al.
JP2018522555A5 (enExample)
JP7770319B2 (ja) ジスルフィド結合の再配列を有するヒトｖｅｇｆ－ａの変異型を含むポリペプチド及びそれを含む組成物
US20210087232A1 (en) D-enantiomeric peptides for anti-inflammatory treatment of amyotropic lateral sclerosis (als) and other diseases driven by neuro-inflammation